Contribute Try STAT+ Today

Arguing patient safety is at risk, an advocacy group is urging the Food and Drug Administration to create a new policy for updating an official list of medicines that are withdrawn after being deemed unsafe or ineffective.

In a petition filed with the agency, Public Citizen noted that the FDA has, in most cases over the past two decades, taken “at least several years” to update this list. Meanwhile, patients could be potentially harmed by compounded formulations that physicians and pharmacists are legally permitted to make in the interim.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • A good example was Rezulin (troglitazone). Most of the world had it off in 6-12 months due to the hepatotoxicity and deaths. U.S. took a little over 2 years. Fortunately my drug committee did not allow coverage of it for our health plan after reviewing it. It was obvious it was going to be a problem from the beginning.

Comments are closed.